PEPG

PepGen Inc. 2024 Q2 10-Q Filing Summary

Business Context and Reporting Period

PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, specifically Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company utilizes its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This report covers the quarterly period ended June 30, 2024. As of August 1, 2024, the company had 32,589,702 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss for the six months ended June 30, 2024, increased by $10.5 million compared to the same period in 2023, driven primarily by higher R&D and G&A expenses.
• R&D Expense Growth: R&D expenses increased by $8.5 million year-over-year for the six-month period. This was attributable to a $6.1 million increase in clinical trial costs and a $4.8 million increase in manufacturing costs for lead programs PGN-EDO51 and PGN-EDODM1, partially offset by a $5.9 million decrease in preclinical costs.
• Capital Raises: In February 2024, the company raised approximately $86.3 million in net proceeds through a Follow-on Offering ($76.4 million) and an At-the-Market (ATM) sale ($9.9 million).
• Liquidity Position: Cash, cash equivalents, and marketable securities increased from $110.2 million at year-end 2023 to $161.3 million at June 30, 2024, reflecting the recent capital raises.

Guidance, Outlook, and Risks

• Clinical Progress:
  • PGN-EDO51 (DMD): Initial data from the CONNECT1 Phase 2 study (5 mg/kg cohort) showed mean exon skipping of 2.15% and dystrophin levels of 1.49% of normal. The drug was well-tolerated. The company expects to report initial results from the 10 mg/kg cohort in early 2025.
  • PGN-EDODM1 (DM1): The Phase 1 FREEDOM study is ongoing. Preliminary data is expected in Q4 2024. The Phase 2 FREEDOM2 study is expected to initiate dosing in the second half of 2024.
• Liquidity Outlook: Management believes current cash and marketable securities ($161.3 million) are sufficient to fund operations into 2026.
• Key Risks:
  • Capital Needs: The company has no approved products and expects to incur losses for the foreseeable future. It will require substantial additional funding to advance clinical trials and commercialize products.
  • Development Uncertainty: Clinical trials are expensive and uncertain. Early positive results (e.g., exon skipping) do not guarantee clinical efficacy or regulatory approval.
  • Regulatory Hurdles: The company previously faced a clinical hold from the FDA for PGN-EDODM1 (lifted in October 2023). Future regulatory interactions could delay timelines.
  • Third-Party Dependence: Reliance on third-party manufacturers and CROs introduces supply chain and operational risks.

Investor Verification Checklist

• Verify the timeline and enrollment status of the CONNECT2 (PGN-EDO51) and FREEDOM2 (PGN-EDODM1) Phase 2 trials.
• Monitor the company's cash burn rate against the stated runway into 2026, especially given the high cost of clinical development.
• Review upcoming data readouts for the 10 mg/kg cohort of PGN-EDO51 (expected early 2025) and the FREEDOM study (expected Q4 2024).
• Assess the impact of potential future dilution if additional equity financing is required before 2026.
• Confirm the status of regulatory filings for the U.S. IND application for the CONNECT2 study, which was expected by year-end 2024.